TY - JOUR
T1 - Outcomes following front-line chemotherapy in peripheral T-cell lymphoma
T2 - 10-year experience at The Royal Marsden and The Christie Hospital
AU - Gleeson, Mary
AU - Peckitt, Clare
AU - Cunningham, David
AU - Gibb, Adam
AU - Hawkes, Eliza A.
AU - Back, Morgan
AU - Yasar, Binnaz
AU - Foley, Kate
AU - Lee, Rebecca
AU - Dash, Joanna
AU - Johnson, Hannah
AU - O’Hara, Catherine
AU - Wotherspoon, Andrew
AU - Attygalle, Ayoma
AU - Menasce, Lia
AU - Shenjere, Patrick
AU - Potter, Mike
AU - Ethell, Mark E.
AU - Dearden, Claire
AU - Radford, John
AU - Chau, Ian
AU - Linton, Kim
PY - 2018
Y1 - 2018
N2 - We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p =.001) and OS (p =.046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
AB - We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p =.001) and OS (p =.046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
KW - chemotherapy
KW - hematopoietic progenitor cell transplant
KW - Peripheral T-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85033697793&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1393671
DO - 10.1080/10428194.2017.1393671
M3 - Article
C2 - 29119842
AN - SCOPUS:85033697793
SN - 1042-8194
VL - 59
SP - 1586
EP - 1595
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -